AbilityPharma is currently completing an international Phase 2b clinical trial with its product ABTL0812 in patients with metastatic pancreatic cancer, a disease with a very low survival rate, with th...
Read more
The Catalan biopharmaceutical company AbilityPharma, focused on the development of innovative oral anticancer compounds, undertakes a collective investment campaign of up to 2 million on the Capital C...
Read more
Carles Domènech, Executive Chairman, Chief Scientific Officer and Co-Founder of AbilityPharma, said: "We are very happy to have reached this agreement with SciClone. This investment represents a cont...
Read more
The Catalan biopharmaceutical company AbilityPharma, focused on the development of innovative oral anticancer compounds, undertakes the last stage of the investment round with which this year it will ...
Read more
The biopharmaceutical company Ability Pharmaceuticals SL announced today that the full description of the mechanism of action of ABTL0812 has been published in the prestigious Autophagy journal (impac...
Read more
The biopharmaceutical company Ability Pharmaceuticals SL announced today that it has been awarded €5 million blended financing from the Horizon Europe, European Innovation Council (EIC) Accelerator ...
Read more
El equipo ejecutivo se refuerza con la incorporación de Maribel Berges como Directora General ascendiendo Carles Domènech a la Presidencia Ejecutiva
Read more
AbilityPharma (Ability Pharmaceuticals, SL) a biopharmaceutical company developing oncology drugs, announced today that the company will release the first results of the currently ongoing phase 1/2...
Read more
Una investigación, liderada por los Dres. Antonio Gil y Eva Colás del Vall d'Hebron Institut de Recerca (VHIR) y por los Dres. Xavier Matias-Guiu y Nuria Eritja del Instituto de Investigación Biome...
Read more
AbilityPharma (Ability Pharmaceuticals, S.L.), una compañía biofarmacéutica catalana especializada en el desarrollo de fármacos oncológicos, ha anunciado hoy que su socio en China, SciClone (SciC...
Read more
La compañía biofarmacéutica AbilityPharma acaba de cerrar una ronda de financiación por valor superior al 1.230.000 euros a través de la plataforma de crowdfunding Capital Cell. Con esta cifra...
Read more
Ability Pharmaceuticals, a drug development biopharmaceutical company specialized in oncology, announced today that it has received orphan-drug designation (ODD) for ABTL0812 from the US Food and Drug...
Read more
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
Un estudio con datos de los últimos 35 años, ind...
En nuestro post hablamos sobre este interesante tipo de célula del...
Research led by IIBB-CSIC and CIBEREHD scientists identifies S-adenosy...
